| 查看: 866 | 回复: 7 | ||||
[交流]
STM：靶向作用脂肪激素或可开发出治疗2型糖尿病的新型疗法
|
||||
|
12月23日，来自哈佛大学的一个研究团队通过研究描述了一种临床前的方法或可帮助治疗2型糖尿病、脂肪肝及其它代谢性疾病，文章中研究者开发了一种抗体，其可以改善通过靶向作用脂肪组织中名为aP2（FABP4）的激素来帮助改善机体的葡萄糖调节，并且降低肥胖小鼠集体的脂肪肝症状。 Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes http://stm.sciencemag.org/content/7/319/319ra205 Kill the messenger A variety of metabolic messengers—many from adipose tissue itself—controls the energy state of organs and organisms. Recently, researchers showed that the fatty acid binding protein aP2, once thought to live and work only in the cytoplasm, is also secreted by adipose tissue and spurs metabolic changes in other organs. Now, Burak and colleagues test whether secreted aP2 can serve as a therapeutic target for type 2 diabetes. In mice, the secreted form of aP2 regulates glucose production in liver, systemic glucose homeostasis, and insulin resistance. Serum levels of aP2 were shown to be elevated in obese mice and humans and to correlate with metabolic complications. The authors identified a monoclonal antibody to aP2 that lowered fasting blood glucose, increased insulin sensitivity, and lowered both fat mass and fatty liver (steatosis) in obese mouse models, relative to a control antibody, but not in aP2-deficient mice. The antidiabetic effects of the therapeutic antibody were linked to the regulation of hepatic glucose output and peripheral glucose utilization. Together, these findings suggest that an aP2-targeted antibody that kills the messenger is a viable approach for diabetes treatment. Abstract The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb–mediated therapeutic constitutes a feasible approach for the treatment of diabetes. |
回复此楼» 收录本帖的淘帖专辑推荐
 新药资讯 |
» 猜你喜欢
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复
-
药学专硕申博
已经有18人回复
-
药理学论文润色/翻译怎么收费?
已经有136人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
广西医科大学基础医学院招收基础医学、药学、生物检验相关专业的研究生
已经有1人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
2026生物医药产业发展大会
已经有0人回复
-
国青中了
已经有23人回复
-
:D多个国家或地区的农药法规&登记情况查询网站
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
2026年人文教育与社会发展国际会议（HESD 2026）
+1/801
-
诚征女友
+1/481
-
重庆医科大学合川医院（合川区人民医院）公开招收博士后研究人员
+1/91
-
浙江农林大学生物质能源团队青年教师招聘通知
+1/88
-
祈祷我们论文发表顺利！！！
+1/83
-
复旦大学化学系材料化学方向招聘博后及科研助理
+3/81
-
沈阳工业大学 环境电化学技术研究团队 招收硕士研究生（学硕/专硕）
+2/60
-
硫化物负极充电充不上去
+2/58
-
中国科学院北京纳米能源与系统研究所 诚招2027级“申请-考核”制普通博士2名
+5/50
-
深圳理工大学—安徽大学 联合招聘博士后多名（电化学储能方向）
+1/45
-
浙江农林大学生物质能源团队青年教师招聘通知
+1/41
-
中国地质大学（武汉）氢能研究院杨明团队-招收27年博士-新能源材料化学及催化
+1/32
-
爱丁顿实验
+1/32
-
大湾区大学-中山大学联合培养2027级博士研究生（二维材料/量子输运/自旋电子学）
+3/31
-
湖南大学-分析检测技术和生物柔性传感器-招收1名博士研究生 (2027年)
+1/23
-
坐标广州，诚征女友，结婚对象，非诚勿扰
+1/21
-
高分辨质谱测试丨科研单位对外服务
+1/18
-
中国科大-合肥国家实验室冷原子量子网络团队招聘启事
+1/12
-
武汉科技大学周志辉教授团队招聘科研助理和师资博后（碳/高分子/富氧/PV/MOF/COF膜）
+1/8
-
上交化院邓楠楠组招收27年春/秋季入学申请考核博士-化学、生物相关方向
+1/7
8楼2016-01-10 22:43:00
简单回复
jiantu2楼
2015-12-29 10:32
回复
linglingchen(金币+1): 谢谢参与
liangbk3楼
2015-12-29 11:05
回复
linglingchen(金币+1): 谢谢参与
tzynew4楼
2015-12-29 12:50
回复
linglingchen(金币+1): 谢谢参与
假大空5楼
2015-12-29 13:24
回复
linglingchen(金币+1): 谢谢参与
2015-12-29 13:42
回复
linglingchen(金币+1): 谢谢参与
好
2016-01-09 22:32
回复
1
